Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 2/20 | 0.58 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.45 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.45 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16479270 | 0.83 | FBP1 (0.56) | FBP1APPMAPTKDM4EALDH1A1 | |
| SCHEMBL16380977 | 0.83 | FBP1 (0.45) | FBP1APPMAPTKDM4EALDH1A1 | |
| SCHEMBL4631989 | 0.81 | FBP1 (0.54) | FBP1APPMAPTKDM4EALDH1A1 | |
| SCHEMBL28247791 | 0.81 | FBP1 (0.54) | FBP1APPMAPTKDM4EALDH1A1 | |
| SCHEMBL4631977 | 0.81 | FBP1 (0.54) | FBP1APPMAPTKDM4EALDH1A1 | |
| SCHEMBL4631972 | 0.81 | FBP1 (0.54) | FBP1APPMAPTKDM4EALDH1A1 | |
| SCHEMBL4631985 | 0.81 | FBP1 (0.54) | FBP1APPMAPTKDM4EALDH1A1 | |
| SCHEMBL15434532 | 0.80 | FBP1 (0.53) | FBP1APPMAPTKDM4EALDH1A1 | |
| SCHEMBL16473939 | 0.79 | FBP1 (0.51) | FBP1APPMAPTKDM4EALDH1A1 | |
| SCHEMBL439935 | 0.77 | APP (0.64) | FBP1APPMAPTALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772268-B2 | Bisphosphonamidate prodrugs and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772268-B2 | Bisphosphonamidate prodrugs and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130090311-A1 | BISPHOSPHONAMIDATE PRODRUGS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090311-A1 | BISPHOSPHONAMIDATE PRODRUGS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2011139791-A2 | BISPHOSPHONAMIDATE PRODRUGS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-11-10 | — | — | WO | disclosed |
| US-7705045-B2 | compounds comprising a specifier linked to two or more of the same or different leaving groups via a self-eliminating multiple release spacer or spacer system, which compounds upon a single activation step, in particular removal or transformation of the specifier, release two or more leaving groups | SYNTARGA, B.V. (NL) | 2010-04-27 | — | — | US | disclosed |
| US-20060116422-A1 | Prodrugs built as multiple self-elimination-release spacers | SYNTARGA B.V. (NL) | 2006-06-01 | — | — | US | disclosed |
| EP-1560599-A1 | PRODRUGS BUILT AS MULTIPLE SELF-ELIMINATION-RELEASE SPACERS | Syntarga B.V. (NL) | 2005-08-10 | — | — | EP | disclosed |
| WO-2004043493-A1 | PRODRUGS BUILT AS MULTIPLE SELF-ELIMINATION-RELEASE SPACERS | SYNTARGA B.V. (NL) | 2004-05-27 | — | — | WO | disclosed |
| EP-0961619-A4 | HYDROLYZABLE PRODRUGS FOR DELIVERY OF ANTICANCER DRUGS TO METASTATIC CELLS | BRISTOL MYERS SQUIBB CO (US) | 2001-09-26 | — | — | EP | disclosed |
| EP-0961619-A1 | HYDROLYZABLE PRODRUGS FOR DELIVERY OF ANTICANCER DRUGS TO METASTATIC CELLS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-12-08 | — | — | EP | disclosed |
| WO-1998013059-A1 | HYDROLYZABLE PRODRUGS FOR DELIVERY OF ANTICANCER DRUGS TO METASTATIC CELLS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116422-A1 | Prodrugs built as multiple self-elimination-release spacers | DNPEP, GUSB, APEH | FBP1 975/4885APP 493/4885MAPT 4176/4885 |
| US-20130090311-A1 | BISPHOSPHONAMIDATE PRODRUGS AND USES THEREOF | BPGM, PHPT1, PFKFB2 | FBP1 8/4885APP 1957/4885MAPT 4506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.